203 results on '"Mourah, Samia"'
Search Results
2. Effect of ultrasound-mediated blood-spinal cord barrier opening on survival and motor function in females in an amyotrophic lateral sclerosis mouse model
3. Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study
4. Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients
5. A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans
6. Metastatic perirectal PEComa treated by checkpoint inhibitor immunotherapy and multimodal treatment: case report and review of the literature.
7. Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
8. Sezary syndrome revealed by PD‐L1 blockade for tumor stage mycosis fungoides
9. Erratum to ‘Molecular profiling of anal Paget’s disease and underlying anal adenocarcinoma highlights their common origin’ [EJC Skin Cancer 1 (2023) 100002]
10. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network
11. Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin
12. Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)
13. Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
14. TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
15. Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov
16. Favorable pharmacokinetics and pharmacodynamics properties of Gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukaemia FLT3-ITD patients
17. Autoimmune diabetes induced by PD-1 inhibitor—retrospective analysis and pathogenesis: a case report and literature review
18. TGF-β-Induced (TGFBI) Protein in Melanoma: A Signature of High Metastatic Potential
19. Molecular profiling of anal Paget’s disease and underlying anal adenocarcinoma highlights their common origin
20. NRAS Mutation Is the Sole Recurrent Somatic Mutation in Large Congenital Melanocytic Nevi
21. Primary cutaneous follicle centre lymphoma with secondary systemic evolution.
22. ZEB1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
23. PARKIN Inactivation Links Parkinson’s Disease to Melanoma
24. Supplementary Figures for Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction
25. Supplementary Materials and Methods for Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction
26. Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction
27. CCR8 is a new therapeutic target in cutaneous T-cell lymphomas
28. EMMPRIN Modulates Epithelial Barrier Function through a MMP–Mediated Occludin Cleavage: Implications in Dry Eye Disease
29. Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
30. Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and plasma samples of melanoma patients by E-ice-COLD-PCR
31. Efficacy of ibrutinib in the treatment of Bing–Neel syndrome
32. EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2α–mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2
33. CD147 Promotes Tumor Lymphangiogenesis in Melanoma via PROX-1
34. Overexpression of Vascular Endothelial Growth Factor 189 in Breast Cancer Cells Leads to Delayed Tumor Uptake with Dilated Intratumoral Vessels
35. Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
36. Fgf2 induces resistance to nilotinib through mapk pathway activation in kit mutated melanoma
37. SIAH-1 interacts with CtIP and promotes its degradation by the proteasome pathway
38. Kaposi's Sarcoma-Associated Herpesvirus Viremia is Associated with the Progression of Classic and Endemic Kaposi's Sarcoma
39. Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes
40. CD147 : rôle et ciblage thérapeutique dans les cancers
41. Discoidin Domain Receptors in Melanoma: Potential Therapeutic Targets to Overcome MAPK Inhibitor Resistance
42. FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma
43. Lack of evidence for the involvement of Merkel cell polyomavirus in pulmonary Langerhans cell histiocytosis
44. Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy
45. Differential Expression of Extracellular Matrix Metalloproteinase Inducer (CD147) in Normal and Ulcerated Corneas: Role in Epithelio-Stromal Interactions and Matrix Metalloproteinase Induction
46. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression
47. Inhibition of EMMPRIN/VEGFR-2 interaction decreases malignant phenotype of melanoma models
48. EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression
49. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement
50. CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.